Climb Bio, Inc.
CLYM
$1.19
-$0.02-1.65%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
4/1/2025
-
The Fly
4/1/2025
-
GuruFocus
4/1/2025
-
Globe Newswire
3/29/2025
-
MarketBeat
3/27/2025
-
GuruFocus
3/27/2025
-
Globe Newswire
3/27/2025
-
TipRanks Financial Blog
3/26/2025
-
MarketBeat
3/25/2025
-
GuruFocus
3/25/2025
-
The Fly
3/25/2025
-
Globe Newswire
3/20/2025
-
MarketBeat
2/25/2025
-
GuruFocus
2/25/2025
-
Globe Newswire
2/24/2025
-
The Fly
2/24/2025
-
GuruFocus
2/24/2025
-
Globe Newswire
2/10/2025
-
MarketBeat
2/4/2025
-
GuruFocus
2/4/2025
-
Globe Newswire
1/23/2025
-
MarketBeat
1/17/2025
-
ETF Channel
1/13/2025
-
Simply Wall St
1/9/2025
-
GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, March 25, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
866 857 2596
Address
20 William Street
Wellesley Hills, MA 02481
Wellesley Hills, MA 02481
Country
Year Founded
Business Description
Sector
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the...
more